Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
-- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow -- -- Conference Call Today at 8:00 a.m. EDT with Investor Materials Available at AdvancingAmarin.com -- DUBLIN, Ireland and BRIDGEWATER,
Amarin Reports First Quarter 2025 Financial Results
-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA ® /VAZKEPA ® -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced it has regained